Introducing a synthetic 7-amino acid peptide
SB-01 is a synthetic 7-amino acid peptide that binds to and induces down regulation of Transforming Growth Factor Beta 1 (TGFβ1), which is often highly expressed in the degenerated discs of patients with lower back pain. Abnormal TGFβ1 signaling is associated with the degradation of extracellular matrix components that maintain the structural integrity of healthy spinal discs. TGFβ1 is also reported to stimulate the expression of nerve growth factor leading to an increase in sensory neurons and discogenic pain. Intradiscal injection of SB-01 in patients with degenerative disc disease was developed as a first-in-class approach to potentially treating chronic back pain and disability, possibly preventing progression of disc degeneration through TGFβ1 modulation.
Please learn more about our Phase 3 clinical trial
Reduce Back
Pain
Restore Function Resulting from Pain-Related Disability
Remove The
Need for Opioids
Introducing a synthetic 7-amino acid peptide
More than a decade of research
Based on more than a decade of research, this novel therapeutic formulation has the potential to improve the lives of millions of people who suffer from chronic low back pain and pain-related disability caused by degenerative disc disease (DDD). Learn more about DDD here.
SB-01 contains a chemically synthesized peptide compound that modulates, in a concentration-dependent manner, the overexpression of Transforming Growth Factor Beta 1 (TGF-β1), an inflammatory cytokine which is known to play a critical role in intervertebral disc degeneration. In preclinical studies, SB-01 demonstrates anti-inflammatory, anti-catabolic, and pro-anabolic effects. The science behind SB-01 has been studied in extensive in vivo, animal and human clinical studies. (1) (2)
The clinical experience with SB-01 offers exciting hope to millions of chronic low back pain sufferers. We hope to share more data with you as it becomes available.
Please learn more about our Phase 3 clinical trial
(2) Kwon, Y. J., Kim, E. S., Kim, S. M., Park, H., Byun, H. M., & Nam, S. Y. (2015). Intradiscal Injection of YH14618, a First-in-Class Disease-Modifying Therapy, Reduces Pain and Improves Daily Activity in Patients with Symptomatic Lumbar Degenerative Disc Disease. The Spine Journal, 15(10), S119. https://doi.org/10.1016/j.spinee.2015.07.093
